A retrospective study of 345 paired tests found 83.5% of patients improved, held steady or declined slowly, with no control group.
On average, the patients in this study were 74.6 years old and living with 9.0 comorbid conditions. They were taking 11.7 medications between them, and according to uMETHOD Health, those medications carried 23 clinically significant drug-drug interactions. Add memory problems on top and you have a chart that no clinician can reasonably untangle in a routine office visit.
That pile is what RestoreU is built to sort through. The North Carolina company describes RestoreU as an AI-based clinical decision support service. It reads a patient’s full medical record over time (diagnoses, medications, lab results, genomics and lifestyle factors) and produces a prioritized care plan for the clinician, patient and caregiver. uMETHOD says it has been commercially deployed since 2016 and works inside the lab and electronic medical record systems clinics already use [1].
The thinking behind it is that cognitive impairment often has several treatable contributors. The release lists medication effects, metabolic health, nutritional deficiencies, sleep, cardiovascular risk and beta amyloid, among others. The tool’s job is to help a clinician see which of those apply to the person in front of them. The company calls the output repeatable and auditable, and says the platform is aligned with Medicare’s cognitive assessment and care planning services. Clinicians don’t have to re-enter decades of patient history into a new interface, which the company sees as a way of reducing friction for providers.
What the study actually looked at
The results were published in Current Aging Science. The paper, by Zelek, Walker and Crocker-Sabbagh, is titled “Real-World Cognitive Stabilization via CDSS-Guided Multidomain Interventions in MCI and Older Adults with Cognitive Concerns.” CDSS is a clinical decision support system and MCI is mild cognitive impairment.
It is a retrospective, nonrandomized analysis of 345 paired cognitive tests. Each pair compares a patient with themselves on the same validated test, once at baseline and once at follow-up, an average of 14.1 months later.
The headline number is 83.5%. That share of patients improved, remained stable, or declined slowly without moving into a worse diagnostic stage. Another 1.7% declined more slowly than typical and did move into the next stage. The follow-up window matters here as well. An average of 14.1 months is a little over a year, which is not long in a condition that tends to unfold over many years.
The release doesn’t say what happened to the remaining patients, or how “typical” was defined. There is also the question of what counts as a win. A patient whose results hold steady over 14 months is a success in this analysis, which is a modest but meaningful goal in a condition defined by decline.
The limits, in the company’s own words
To its credit, uMETHOD doesn’t dodge the obvious objection. John Q. Walker, co-founder, Chief Technology Officer and principal inventor of RestoreU, said: “This is a real-world retrospective study, not a randomized controlled trial. There is no usual-care comparison group, and we’re careful not to claim more than the data support.”
With no comparison group, a stable score can’t be credited to the care plan with any certainty, since cognitive trajectories vary a lot from person to person and some people with early-stage impairment hold steady for a good while on their own. Studies built this way also tend to capture only the patients who came back for a second test. A randomized trial would be the cleaner way to answer the question, and the release doesn’t mention plans for one.
Behavioral neurologist Dr Marwan Sabbagh was more enthusiastic, saying clinicians have spent years debating drug approaches while factors they can actually change, such as medications, metabolic health, sleep, nutrition and vascular risk, went unaddressed in routine care. He described the approach as “systematic enough for any physician to repeat.”
Why the scale matters
The company frames the work against a large backdrop. According to the Alzheimer’s Association, 7.4 million Americans age 65 and older are living with Alzheimer’s or dementia, and health care, long-term care and hospice costs for people with these conditions will reach $409 billion in 2026, not counting unpaid family caregiving.
This is where the story touches longevity. Cognitive decline is among the outcomes people fear most about living longer, and the levers on uMETHOD’s list are the same everyday ones longevity medicine keeps returning to. Sleep, metabolic health, nutrition and blood vessel health are hardly exotic. The novelty here is trying to review all of them systematically, patient by patient, using software that fits into an ordinary clinic. Because the approach works through existing medications and everyday factors, it doesn’t depend on a new drug reaching approval.
Whether that changes the course of disease is a question this study can’t answer, and its authors say as much. What it does offer is an early look at what the approach produces when used in routine practice.
